{
  "source": "PA-Notification-Olumiant.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 1249-9\nProgram Prior Authorization/Notification\nMedication Olumiant® (baricitinib)\nP&T Approval Date 7/1/2108, 7/2019, 7/2020, 7/2021, 2/2022, 8/2022, 7/2023, 9/2023,\n10/2024\nEffective Date 1/1/2025\n1. Background:\nOlumiant (baricitinib) is a Janus Kinase (JAK) inhibitor indicated for the treatment of adult\npatients with moderately to severely active rheumatoid arthritis who have had an inadequate\nresponse to one or more tumor necrosis factor (TNF) antagonist therapies and for the\ntreatment of adult patients with severe alopecia areata. Use of Olumiant in combination\nwith other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as\nazathioprine and cyclosporine is not recommended. Olumiant is also indicated for the\ntreatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive\nor invasive mechanical ventilation, or ECMO.1\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Olumiant will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active RA\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF antagonist\ntherapy\n-AND-\n(3) Patient is not receiving Olumiant in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Orencia (abatacept), Rinvoq (upadacitinib), Simponi\n(golimumab), Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Olumiant will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Olumiant therapy\n-AND-\n(2) Patient is not receiving Olumiant in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etane",
    "sponse to Olumiant therapy\n-AND-\n(2) Patient is not receiving Olumiant in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Orencia (abatacept), Rinvoq (upadacitinib), Simponi\n(golimumab), Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nB. Alopecia Areata\n1. Initial Authorization\na. Olumiant will be approved based on both of the following criteria:\n(1) Diagnosis of severe alopecia areata\n-AND-\n(2) Patient is not receiving Olumiant in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Orencia (abatacept), Rinvoq (upadacitinib), Simponi\n(golimumab), Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Olumiant will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Olumiant therapy\n-AND-\n(2) Patient is not receiving Olumiant in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Orencia (abatacept), Rinvoq (upadacitinib), Simponi\n(golimumab), Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes var",
    "thcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Step Therapy, and/or Medical Necessity may be in place.\n4. References:\n1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; June 2022.\n2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology\nGuideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis\nRheum. 2021;73(7):924-939.\nProgram Prior Authorization/Notification – Olumiant (baricitinib)\nChange Control\n7/2018 New program.\n7/2019 Annual review. No changes to the program.\n7/2020 Annual review. Updated reauthorization issue duration.\n7/2021 Annual review. No changes to coverage criteria.\n2/2022 Added Rinvoq as an example of JAKi. Updated references.\n8/2022 Added coverage criteria for alopecia areata. Updated background and\nreference. Added state mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n9/2023 Updated examples. No change to coverage criteria.\n10/2024 Annual review. Updated example with no change to clinical intent.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}